Unique ID issued by UMIN | UMIN000009531 |
---|---|
Receipt number | R000011187 |
Scientific Title | Study on treatment after complete resection of high risk gastrointestinal stromal tumor (GIST) |
Date of disclosure of the study information | 2012/12/13 |
Last modified on | 2022/06/20 14:38:12 |
Study on treatment after complete resection of high risk gastrointestinal stromal tumor (GIST)
STAR ReGISTry
Study on treatment after complete resection of high risk gastrointestinal stromal tumor (GIST)
STAR ReGISTry
Japan |
Gastrointestinal stromal tumor
Gastroenterology | Gastrointestinal surgery |
Malignancy
YES
The purpose of this study is to register patients who have undergone a curative resection (R0/R1 resection) in an initial gastrointestinal stromal tumor (GIST) and have been found to have high risk based on the modified-Fletcher Classification (Joensuu) and to study conditions and prognosis of their post surgical treatments. This study also covers an exploration of appropriate imatinib treatment period.
Safety,Efficacy
Exploratory
Not applicable
Recurrence-free survival
-Overall survival
-Occurrence and severity of adverse events
-Completion of treatment
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1) The diagnosis of GIST is confirmed by KIT-positive of resected specimen or acquiring of genetic mutations with c-kit and PDGFRA
2) The subject is classified as high risk based on the modified-Fletcher Classification (Joensuu)
3) In initial GIST, a complete gross resection had been conducted and the resection is within 3 years prior to registration (if recurrence is found at the time, the registration shall be permitted when above condition is met.)
4) Over 20 years old
5) Patients are able to provide written informed consent, if the patient died at the time of registration, a consent must be obtained from the legal representative of the person
(Unless it has been six months or more after the surgery)
6) After the surgery, a periodic imaging test (every 6 months) has been conducted to examine possibility of recurrence
1) In case the patient has other serious illnesses other than GIST (other cancer, cardiovascular disease, brain disease, and hepatorenal diseases etc).
2) Resection of metastases/ disseminated lesion was concluded in initial GIST, a complete gross resection
3) In case the physician determines that participation in the study is not appropriate.
500
1st name | Toshirou |
Middle name | |
Last name | Nishida |
National Cancer Center Hospital
Department of Surgery
104-0045
5-1-1 Tsukiji, Chuoku, Tokyo 104-0045, Japan
03-3542-2511
tnishida@ncc.go.jp
1st name | Satoshi |
Middle name | |
Last name | Nakagawa |
Translational Research Center for Medical Innovation
None
650-0047
1-5-4 Minatojima-minamimachi, Chuo-ku, Kobe, Japan 650-0047
078-303-9093
http://www.tri-kobe.org/
s-nakagawa@tri-kobe.org
The Research Group for Rare Neoplasms of Japan
Novartis Pharma K.K.
Profit organization
National Cancer Center
5-1-1 Tsukiji, Chuoku, Tokyo 104-0045, Japan
03-3542-2511
tnishida@ncc.go.jp
NO
国立研究開発法人 国立がん研究センター 中央病院(東京都)
国立研究開発法人 国立がん研究センター 東病院(千葉県)
大阪警察病院(大阪府)
大阪大学医学部付属病院(大阪府)
2012 | Year | 12 | Month | 13 | Day |
Unpublished
Completed
2012 | Year | 11 | Month | 07 | Day |
2012 | Year | 11 | Month | 07 | Day |
2012 | Year | 12 | Month | 25 | Day |
2019 | Year | 12 | Month | 31 | Day |
2020 | Year | 03 | Month | 31 | Day |
2020 | Year | 09 | Month | 30 | Day |
2021 | Year | 10 | Month | 31 | Day |
prospective non-interventional study
2012 | Year | 12 | Month | 12 | Day |
2022 | Year | 06 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011187